The drug landscape for major depressive disorder (MDD) consists of numerous safe and effective treatment options, many of which are available as inexpensive generics. Agents for treating MDD span multiple drug classes, most notably selective serotonin reuptake inhibitors (SSRIs) and serotonin / norepinephrine reuptake inhibitors (SNRIs), while other agents, including the newer-to-market Spravato (Janssen Pharmaceuticals’ esketamine), offer distinct mechanisms of action. Treatment is often a trial-and-error process due to the heterogeneous nature of the patient population and the multitude of drugs available to treat depressive symptoms. As such, the MDD treatment paradigm is highly individualized and complex. This report provides physician insights into prescribing decisions in this complex disease.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 51 psychiatrists and 51 primary care physicians in the United States.
Key companies: Allergan, AstraZeneca, Bausch Health, Janssen Pharmaceuticals, Lundbeck, Otsuka Pharmaceutical, Sunovion, Takeda Pharmaceutical
Key drugs: Aplenzin, aripiprazole, Latuda, quetiapine XR, Rexulti, sertraline, Spravato, Trintellix
Key insights provided: